GlaxoSmithKline on Thursday said that a lab analysis of the antibody-based COVID-19 therapy it is developing with US partner Vir has shown the drug is effective against the new Omicron variant.
Follow Israel Hayom on Facebook and Twitter
In a statement, the British drugmaker said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant.
The tests are ongoing to confirm the results against all of the Omicron mutations with an update expected by year-end, it added.
Separately, Britain's drug regulator on Thursday approved sotrovimab, also known under the brand name Xevudy, for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
